Patent · US Expired

Rationally designed antibodies

US7482435B2 · kind B2 · utility

15Cited by

33References

53Claims

0Family size

Assignee

Alexion Pharmaceuticals, Inc. · US

Inventors

Katherine S. Bowdish · Del Mar, US
Shana Frederickson · Solana Beach, US
Mark Renshaw · San Diego, US

Key dates

Filing date	Dec 5, 2001
Grant date	Jan 27, 2009
Priority date	—
Expiry date	Dec 5, 2021

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2506/11
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Antibodies or fragments thereof having CDR regions replaced or fused with biologically active peptides are described. Flanking sequences may optionally be attached at one or both the carboxy-terminal and amino-terminal ends of the peptide in covalent association with adjacent framework regions. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.